ME/CFS Conference 2025 in Berlin

The 3rd International ME/CFS Conference on May 12 and 13, 2025 in Berlin was a complete success. Organized by the Charité Fatigue Center (headed by Prof. Dr. Carmen Scheibenbogen), experts from all over the world gave lectures on aspects of pathogenesis, diagnostics and – most importantly – treatment options. The importance of the GPCR autoantibody…

Details

Price adjustment

Dear customers, Thank you for your trust in our products and services. Due to the increased costs of our consumables in recent years, we have had to adjust our prices, which have been in force since 2018. We ask for your understanding that this increase is necessary in order to be able to guarantee you…

Details

International ME/CFS Conference 2025

Under the direction of Prof. Dr. Carmen Scheibenbogen (Charité, Berlin), the 3rd International Meeting of the Charité Fatigue Center will take place on 12.05.25 and 13.05.25. The two-day hybrid conference will be broadcast live from the Harnack House of the Max Planck Society in Berlin and will present the latest research findings by physicians and…

Details

CellTrend sponsores the LemonChallengeMECFS

The Long Covid pandemic has doubled the number of people with the disease to around 40 million worldwide. The #LemonChallengeMECFS aims to raise awareness of the serious illness ME/CFS. ME/CFS occurs primarily after infections (e.g. COVID-19, influenza, EBV). It can affect anyone. Unfortunately, there is no treatment yet, which is why the ME/CFS Research Foundation…

Details

Presentation of a new GLP1-R autoantibody ELISA test in Kuwait

On 04.02.2025 the Transcampus Roadshow of Prof. Dr. Stefan Bornstein (Clinic Director of the University Hospital Dresden) took place in Kuwait. Prof. Dr. Kai Schulze-Forster, founder of CellTrend GmbH, presented the ELISA test for the quantitative detection of GLP1-R autoantibodies (#17900). CellTrend has already applied for patent protection for the GLP1-R-AB ELISA (GLP-1R AUTO-ANTIBODIES AS…

Details

Study about autoantibodies targeting GPCR in PACVS

A new study about autoantibodies targeting G-Protein-Coupled Receptors (GPCRs) in Post-Acute COVID Vaccination Syndrome (PACVS) was published. This study included 17 patients with symptoms compatible with PACVS after COVID-19 vaccination but they had not been infected with SARS-CoV-2. Serological tests showed that a high percentage of patients were positive for autoantibodies against GPCRs which are…

Details